Pharmacokinetic Properties of IgG and Various Fc Fusion Proteins in Mice

Overview

Journal MAbs

Specialty Allergy & Immunology

Date 2015 Oct 31

PMID 26514880

Citations 49

Authors

Felix Unverdorben

Fabian Richter

Meike Hutt

Oliver Seifert

Pauline Malinge

Nicolas Fischer

Roland E Kontermann

Affiliations

Soon will be listed here.

Abstract

Fusion to an IgG Fc region is an established strategy to extend the half-life of therapeutic proteins. Most Fc fusion proteins, however, do not achieve the long half-life of IgGs. Based on findings that scFv-Fc fusion proteins exhibit a shorter half-life than the corresponding IgG molecules, we performed a comparative study of different antibody-derived Fc fusion proteins. We could confirm that fusion of single-chain Fv (scFv) and single-chain diabody (scDb) molecules to an Fc region yields in fusion proteins with substantially extended half-lives compared with the single-chain versions. However, even fusion proteins with a size similar to that of IgG, e.g., scDb-Fc, did not have a half-life as long as an IgG molecule. Binding to the neonatal Fc receptor (FcRn) under acidic and neutral conditions was similar for IgG and all Fc fusion proteins. However, we observed differences between IgG and the Fc fusion proteins for dissociation of FcRn-bound proteins induced by shifting from acidic to neutral pH, reflecting the physiological release mechanism, further supporting a contribution of the kinetics of pH-dependent release from FcRn to the pharmacokinetic properties of IgG and Fc fusion proteins.

Citing Articles

Kinetics of Nirogacestat-Mediated Increases in B-cell Maturation Antigen on Plasma Cells Inform Therapeutic Combinations in Multiple Myeloma.

Shearer T, Comstock M, Williams Jr R, Johnson M, Cendrowicz E, Leonowens C Cancer Res Commun. 2024; 4(12):3114-3123.

PMID: 39530736 PMC: 11632591. DOI: 10.1158/2767-9764.CRC-24-0075.

Human antibodies neutralizing the alpha-latrotoxin of the European black widow.

Ruschig M, Nerlich J, Becker M, Meier D, Polten S, Cervantes-Luevano K Front Immunol. 2024; 15:1407398.

PMID: 38933276 PMC: 11199383. DOI: 10.3389/fimmu.2024.1407398.

Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins.

Liu S, Li Y, Li Z, Wu S, Harrold J, Shah D J Pharmacokinet Pharmacodyn. 2024; 51(5):449-476.

PMID: 38691205 DOI: 10.1007/s10928-024-09922-x.

Enhanced Immunogenicity and Protective Effects against SARS-CoV-2 Following Immunization with a Recombinant RBD-IgG Chimeric Protein.

Silva M, Castro-Amarante M, Venceslau-Carvalho A, Almeida B, Daher I, Souza-Silva G Vaccines (Basel). 2024; 12(4).

PMID: 38675739 PMC: 11054318. DOI: 10.3390/vaccines12040356.

Optimized Production of Fc Fusion Proteins by Sortase Enzymatic Ligation.

Apley K, Laflin A, Johnson S, Batrash N, Griffin J, Berkland C Ind Eng Chem Res. 2024; 60(47):16839-16853.

PMID: 38646185 PMC: 11031256. DOI: 10.1021/acs.iecr.1c02842.

References

Schoch A, Kettenberger H, Mundigl O, Winter G, Engert J, Heinrich J . Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci U S A. 2015; 112(19):5997-6002. PMC: 4434771. DOI: 10.1073/pnas.1408766112. View

Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T . Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol. 2010; 184(4):1968-76. DOI: 10.4049/jimmunol.0903296. View

Souders C, Nelson S, Wang Y, Crowley A, Klempner M, Thomas Jr W . A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life. MAbs. 2015; 7(5):912-21. PMC: 4622054. DOI: 10.1080/19420862.2015.1054585. View

Hombach A, Heuser C, Abken H . Simultaneous targeting of IL2 and IL12 to Hodgkin's lymphoma cells enhances activation of resting NK cells and tumor cell lysis. Int J Cancer. 2005; 115(2):241-7. DOI: 10.1002/ijc.20829. View

Korn T, Muller R, Kontermann R . Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes. J Immunother. 2004; 27(2):99-106. DOI: 10.1097/00002371-200403000-00003. View

Kenanova V, Olafsen T, Crow D, Sundaresan G, Subbarayan M, Carter N . Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res. 2005; 65(2):622-31. PMC: 4154799. View

Muller D, Karle A, Meissburger B, Hofig I, Stork R, Kontermann R . Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem. 2007; 282(17):12650-60. DOI: 10.1074/jbc.M700820200. View

Gehlsen K, Gong R, Bramhill D, Wiersma D, Kirkpatrick S, Wang Y . Pharmacokinetics of engineered human monomeric and dimeric CH2 domains. MAbs. 2012; 4(4):466-74. PMC: 3499341. DOI: 10.4161/mabs.20652. View

Magistrelli G, Malinge P, Anceriz N, Desmurs M, Venet S, Calloud S . Robust recombinant FcRn production in mammalian cells enabling oriented immobilization for IgG binding studies. J Immunol Methods. 2011; 375(1-2):20-9. DOI: 10.1016/j.jim.2011.09.002. View

10.

Gurbaxani B, Dostalek M, Gardner I . Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?. Mol Immunol. 2013; 56(4):660-74. DOI: 10.1016/j.molimm.2013.05.008. View

11.

Sola R, Griebenow K . Effects of glycosylation on the stability of protein pharmaceuticals. J Pharm Sci. 2008; 98(4):1223-45. PMC: 2649977. DOI: 10.1002/jps.21504. View

12.

Vaccaro C, Zhou J, Ober R, Ward E . Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol. 2005; 23(10):1283-8. DOI: 10.1038/nbt1143. View

13.

Lencer W, Blumberg R . A passionate kiss, then run: exocytosis and recycling of IgG by FcRn. Trends Cell Biol. 2005; 15(1):5-9. DOI: 10.1016/j.tcb.2004.11.004. View

14.

Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C . Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel. 2010; 23(5):385-92. DOI: 10.1093/protein/gzq009. View

15.

Levin D, Golding B, Strome S, Sauna Z . Fc fusion as a platform technology: potential for modulating immunogenicity. Trends Biotechnol. 2014; 33(1):27-34. DOI: 10.1016/j.tibtech.2014.11.001. View

16.

Wu A, Senter P . Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005; 23(9):1137-46. DOI: 10.1038/nbt1141. View

17.

Stork R, Zettlitz K, Muller D, Rether M, Hanisch F, Kontermann R . N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. J Biol Chem. 2008; 283(12):7804-12. DOI: 10.1074/jbc.M709179200. View

18.

Proetzel G, Wiles M, Roopenian D . Genetically engineered humanized mouse models for preclinical antibody studies. BioDrugs. 2013; 28(2):171-80. PMC: 4414315. DOI: 10.1007/s40259-013-0071-0. View

19.

Ward E, Devanaboyina S, Ober R . Targeting FcRn for the modulation of antibody dynamics. Mol Immunol. 2015; 67(2 Pt A):131-41. PMC: 4529761. DOI: 10.1016/j.molimm.2015.02.007. View

20.

Wu A . Engineered antibodies for molecular imaging of cancer. Methods. 2013; 65(1):139-47. PMC: 3947235. DOI: 10.1016/j.ymeth.2013.09.015. View